2. A platform for screening and systematic pharmacodynamic evaluation of antitumor drugs targeting receptor tyrosine kinases c-Met, ALK and FGFR was established for the first time in China. Up to now, several candidate compounds with deep research value have been obtained (Org Biomol Chem 20 13, J Med Chem 20 1 1, chemeur j 201). Among them, two targeted anti-tumor drugs SIMM244 and SAF 189 are undergoing systematic preclinical research.
3. The second heparanase inhibitor JG3(Cancer Res 2006) was developed, and its antitumor activity was better than that of the first inhibitor PI88. On this basis, further studies have proved that the same series of compounds JG6 can target mitogen, thus inhibiting tumor metastasis. This study opens up a new way for developing anti-tumor metastasis drugs targeting cofilin (Oncotarget 20 14).
4. It is found that pIgR is an important marker of early recurrence and metastasis of hepatocellular carcinoma. It was found that pIgR could induce epithelial-mesenchymal transition (EMT) and promote the early recurrence and metastasis of hepatocellular carcinoma (J NATL cancer INST 2011; American Journal of Gastroenterology (2006). The research results have challenged the limitations of traditional functions of pIgR, laid an important theoretical foundation for redefining the "non-classical functions" of immunoglobulin receptor family, and provided the first important example for the study of the dual nature of immunoglobulin receptor (review by J Natl Cancer Inst in the same period). It reveals the new function of immune betrayal of immunoglobulin receptor pIgR, and proves that pIgR is an important symbol of early recurrence of liver cancer.